Every material Form 8-K ImageneBio, Inc. has filed with the SEC since June 26, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
ImageneBio reported a second-quarter 2026 net loss of $10.2 million, or $0.63 per share, up from a net loss of $7.6 million a year earlier, with no license revenue in either period. The company said its $136.2 million in cash and marketable securities should fund planned operations into the first quarter of 2028, and that the Phase 2b ADAPTIVE trial of olevaprubart in atopic dermatitis continues under an amended protocol with topline data expected in the fourth quarter of 2027.
Net loss was $10.2 million for the quarter ended June 30, 2026, versus $7.6 million in the same quarter of 2025; G&A expenses rose to $5.1 million from $1.7 million.
Loss per share was $0.63, compared with $4.46 a year earlier; the 2025 figure reflected a smaller share count and $3.1 million in preferred stock accretion.
Cash, cash equivalents and marketable securities totaled $136.2 million as of June 30, 2026, after a $30 million private placement closed in April 2026.
Yanina Grant-Huerta was appointed Chief Financial Officer and Matt Robbins General Counsel; the ADAPTIVE trial's data monitoring committee recommended the study proceed unchanged on July 23, 2026.
ImageneBio appointed Yanina Grant-Huerta as Chief Financial Officer effective July 20, 2026, replacing CEO Kristin Yarema, who had been serving as interim principal financial officer. Separately, Chief Medical Officer Benjamin Porter-Brown will move from a full-time role to a consulting role effective July 24, 2026.
Grant-Huerta receives a $450,000 annual base salary and a 40% target discretionary bonus, plus a 65,000-share RSU grant and a 95,000-share stock option grant.
Her severance terms include 12 months of base salary and continued group health benefits for up to 12 months, with enhanced change-in-control benefits.
Grant-Huerta previously served as Chief Accounting Officer at Atara Biotherapeutics from March 2025 to July 2026 and spent 14 years at Amgen before that.
Dr. Porter-Brown will continue as a consulting clinical development expert and strategic advisor.
ImageneBio said Robert Lally, its Senior Vice President of Finance and Operations and principal accounting officer, gave notice of his resignation on June 22, 2026, effective July 22, 2026. The company said the departure was not due to any disagreement and that it plans to search for a replacement.
Robert Lally, SVP of Finance and Operations and principal accounting officer, resigned.
Notice given June 22, 2026; resignation effective July 22, 2026.
Company states no disagreement led to the resignation.
ImageneBio plans to search for a replacement; no successor named in the filing.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every ImageneBio, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →